|
1.
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Rosell R, Monzo M, Molina F, et al: K-ras
genotypes and prognosis in non-small-cell lung cancer. Ann Oncol.
6:S15–S20. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Takano T, Fukui T, Ohe Y, et al: EGFR
mutations predict survival benefit from gefitinib in patients with
advanced lung adenocarcinoma: a historical comparison of patients
treated before and after gefitinib approval in Japan. J Clin Oncol.
26:5589–5595. 2008. View Article : Google Scholar
|
|
5.
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ferguson PJ, Collins O, Dean NM, et al:
Antisense down-regulation of thymidylate synthase to suppress
growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa
cells. Br J Pharmacol. 127:1777–1786. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Flynn J, Berg RW, Wong T, et al:
Therapeutic potential of antisense oligodeoxynucleotides to
down-regulate thymidylate synthase in mesothelioma. Mol Cancer
Ther. 5:1423–1433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Lin SB, Ts’o PO, Sun SK, et al: Inhibition
of thymidylate synthase activity by antisense oligodeoxynucleotide
and possible role in thymineless treatment. Mol Pharmacol.
60:474–479. 2001.PubMed/NCBI
|
|
9.
|
Hann N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Okamoto I, Yoshioka H, Morita S, et al:
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel
plus carboplatin in chemotherapy-naive patients with advanced
non-small-cell lung cancer: result of a West Japan oncology group
study. J Clin Oncol. 20:5240–5246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shirota Y, Stoehlmacher J, Brabender J, et
al: ERCC1 and thymidylate synthase mRNA level predict survival for
colorectal cancer patients receiving combination oxaliplatin and
fluorouracil chemotherapy. J Clin Oncol. 19:4298–4304. 2001.
|
|
12.
|
Nishimura R, Nagao K, Miyayama H, et al:
Thymidylate synthase levels as a therapeutic and prognostic
predictor in breast cancer. Anticancer Res. 19:5621–5626.
1999.PubMed/NCBI
|
|
13.
|
Takamura M, Nio Y, Yamasawa K, et al:
Implication of thymidylate synthase in the outcome of patients with
invasive ductal carcinoma of the pancreas and efficacy of adjuvant
chemotherapy using 5-fluorouracil or its derivatives. Anticancer
Drugs. 13:75–85. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zheng Z, Li X, Schell MJ, et al:
Thymidylate synthase in situ protein expression and survival in
stage I non small-cell lung cancer. Cancer. 112:2765–2773. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Chen CY, Chang YL, Shin JY, et al:
Thymidylate synthase and dihydrofolate reductase expression in
non-small cell lung carcinoma: the association with treatment
efficacy of pemetrexed. Lung Cancer. 74:132–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Non-small Cell Lung Cancer Collaborative
Group: Chemotherapy in non-small cell lung cancer: a meta-analysis
using updated date on individual patients from 52 randomized
clinical trials. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Olaussen KA, Dunant A, Fouret P, et al
IALT Bio Investigators: DNA repair by ERCC1 in non-small cell lung
cancer and cisplatin-based adjuvant chemotherapy. N Eng J Med.
355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Yin S, Bhattacharya R and Cabral F: Human
mutations that confer paclitaxel resistance. Mol Cancer Ther.
9:327–335. 2010. View Article : Google Scholar
|
|
19.
|
Lenz HJ, Leichman CG, Danenberg KD, et al:
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a
predictor for primary tumor response and overall survival. J Clin
Oncol. 14:176–182. 1996.PubMed/NCBI
|
|
20.
|
Ceppi P, Volante M, Saviozzi S, et al:
Squamous cell carcinoma of the lung compared with other histotypes
shows higher messenger RNA and protein levels for thymidylate
synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Suzuki H, Takahashi T, Kuroishi T, et al:
p53 mutations in non-small cell lung cancer in Japan: association
between mutations and smoking. Cancer Res. 52:734–736.
1992.PubMed/NCBI
|
|
22.
|
Ahrendt SA, Decker PA, Alawi EA, et al:
Cigarette smoking is strongly associated with mutation of the K-ras
gene in patients with primary adenocarcinoma of the lung. Cancer.
92:1525–1530. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Mitsudomi T, Oyama T, Nishida K, et al:
Loss of heterozygosity at 3p in non-small cell lung cancer and its
prognostic implication. Clin Cancer Res. 2:1185–1189.
1996.PubMed/NCBI
|
|
24.
|
Johnston PG, Fisher ER, Rocktte HE, et al:
The role of thymidylate synthase expression in prognosis and
outcome of adjuvant chemotherapy in patients with rectal cancer. J
Clin Oncol. 12:2640–2647. 1994.PubMed/NCBI
|
